Tissue Engineering: Building a better model of the retina

Researchers have combined organ-on-a-chip engineering with the benefits of organoids to make improved models of the human retina.
  1. Milica Radisic  Is a corresponding author
  1. University of Toronto, Canada

A lot of what is known about human cells has come from studying cultures that have been grown in a dish. However, these two-dimensional cultures do not accurately represent the native environment in which our cells grow. Over the past decade both bioengineers and stem cell biologists have created three-dimensional cell cultures that promise to provide a more reliable model for studying human tissue. Bioengineers, for example, have been creating ‘organ-on-a-chip’ devices that precisely control the various cues that act on cells (Huh et al., 2010; Zhang et al., 2016). Using these devices, bioengineers have been able to reproduce the three-dimensional environments of certain tissues, including heart and lung tissues, in a way that captures some aspects of how these organs work (Zhang et al., 2018).

Stem cell biologists, on the other hand, have relied on the inherent ability of stem cells to undergo differentiation in a three-dimensional environment, and to create cell masses called organoids that exhibit some complexity of native organs, including the brain (Lancaster et al., 2013; Lancaster and Knoblich, 2014) and kidney (Phipson et al., 2019). There is no doubt that organoids provide a more faithful representation of native tissue than organ-on-a-chip devices, which typically contain at most two to three different cell types. However, organoids exhibit a lot of variability and this, along with their small size, means they cannot easily be used to study how an organ may respond to different drugs. Although organ-on-a-chip devices are generally considered to be less biologically representative, they do offer a more controlled environment for studying the effects of drugs. Therefore, the natural way forward for both these fields would be to combine the advantages of organoids and organ-on-a-chip devices in a single system (Takebe et al., 2017).

Human vision is particularly difficult to study using animal models, since the fundamental characteristics of how we see are different to most animals. This has motivated researchers to use models of the human retina that have been explanted post-mortem, but these can display a lot of donor-donor variability and various disease-related conditions. Recently, researchers have used pluripotent stem cells to generate an organoid of the human retina that has a similar structure to the real thing (Zhong et al., 2014). However, for these models to accurately represent the in vivo environment of the retina, they must also have a blood supply that provides the retina with nutrients. Now, in eLife, Peter Loskill (Fraunhofer Institute and University of Tübingen), Stefan Liebau (University of Tübingen) and colleagues – including Kevin Achberger, Christopher Probst and Jasmin Haderspeck – report the creation of a retina-on-a chip device that reproduces the vascular supply to the retina in vitro using specially designed micro-channels (Achberger et al., 2019).

To create the device, Achberger et al. combined organoids of the human retina with retinal pigment epithelial (RPE) cells, which form part of the complex environment of the human retina in vivo. Each chip has four compartments designed to hold a single organoid, which sit above a porous membrane that separates the retina from the vasculature-like compartment below (Figure 1): First, RPE cells were seeded onto the membrane, followed by the organoids which had been cultured for 180 days prior to plating to ensure they had reached maturity. This design allows small molecules, nutrients, and proteins from the media in the vascular-like channels to diffuse across the porous membrane where they can be transported from the retinal epithelium into the organoids, similar to how transport occurs in vivo. Secreted factors are then carried away from the retina tissue via the flow of fluids which are confined to the vasculature-like channels below.

Retina-on-a-chip combines the benefits of organoids and organ-on-a-chip engineering.

Each chip has a vascular-like compartment (red) which is separated from the four organoid compartments above by a porous membrane. Schematic diagram (right) showing the various layers of cells in the retinal organoid (top) and the retinal pigment epithelium cells (RPE; yellow).

Image credit: Achberger et al. (CC BY 4.0)

This retina-on-a-chip device generated by Achberger et al. is the first tissue model to reproduce the specific layer configuration of seven different cell types in the human retina. The organoids seeded into the device expressed markers of major retinal cells such as ganglion cells, bipolar cells, horizontal cells, amacrine cells, Müller glia and photoreceptors. Notably, Achberger et al. showed that RPE cells directly interacted with the outer segment of photoreceptors in the retinal organoid through phagocytosis. They also observed that cells in the organoid formed specific layers that were similar to how retinal cells are structurally organized in vivo (Figure 1). Achberger et al. also found that these devices could reproduce the visual side-effects of the anti-malaria drug choroquine and the antibiotic gentamicin, indicating that these retina models could be used for drug testing.

The retina is an especially difficult organ to model due to the large number of different cell types involved and its complex structure, so the device created by Achberger et al. is at the very forefront of the organ-on-a-chip field. Further studies should focus on: enhancing the throughput of device production and cell cultivation, automating the plating of cells and measurements taken, and eliminating the use of drug absorbing materials. The new device promises to decrease the reliance on animal models in retinal drug testing and could be used to study the effects of new drugs on human retinas before starting clinical trials. This retina model could therefore have a huge impact on drug discovery and safety testing.

References

Article and author information

Author details

  1. Milica Radisic

    Milica Radisic is in the Department of Chemical Engineering and Applied Chemistry, Institute of Biomaterials and Biomedical Engineering, and Toronto General Research Institute, University of Toronto, Toronto, Canada

    For correspondence
    m.radisic@utoronto.ca
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1249-4135

Publication history

  1. Version of Record published:

Copyright

© 2019, Radisic

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,116
    views
  • 216
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Milica Radisic
(2019)
Tissue Engineering: Building a better model of the retina
eLife 8:e51183.
https://doi.org/10.7554/eLife.51183

Further reading

    1. Medicine
    2. Neuroscience
    Chi Zhang, Qian Huang ... Yun Guan
    Research Article

    Pain after surgery causes significant suffering. Opioid analgesics cause severe side effects and accidental death. Therefore, there is an urgent need to develop non-opioid therapies for managing post-surgical pain. Local application of Clarix Flo (FLO), a human amniotic membrane (AM) product, attenuated established post-surgical pain hypersensitivity without exhibiting known side effects of opioid use in mice. This effect was achieved through direct inhibition of nociceptive dorsal root ganglion (DRG) neurons via CD44-dependent pathways. We further purified the major matrix component, the heavy chain-hyaluronic acid/pentraxin 3 (HC-HA/PTX3) from human AM that has greater purity and water solubility than FLO. HC-HA/PTX3 replicated FLO-induced neuronal and pain inhibition. Mechanistically, HC-HA/PTX3-induced cytoskeleton rearrangements to inhibit sodium current and high-voltage activated calcium current on nociceptive DRG neurons, suggesting it is a key bioactive component mediating pain relief. Collectively, our findings highlight the potential of naturally derived biologics from human birth tissues as an effective non-opioid treatment for post-surgical pain. Moreover, we unravel the underlying neuronal mechanisms of pain inhibition induced by FLO and HC-HA/PTX3.

    1. Medicine
    Sami Fawaz, Severine Marti ... Thierry Couffinhal
    Research Article

    Background:

    Clonal hematopoiesis of indeterminate potential (CHIP) was initially linked to a twofold increase in atherothrombotic events. However, recent investigations have revealed a more nuanced picture, suggesting that CHIP may confer only a modest rise in myocardial infarction (MI) risk. This observed lower risk might be influenced by yet unidentified factors that modulate the pathological effects of CHIP. Mosaic loss of the Y chromosome (mLOY), a common marker of clonal hematopoiesis in men, has emerged as a potential candidate for modulating cardiovascular risk associated with CHIP. In this study, we aimed to ascertain the risk linked to each somatic mutation or mLOY and explore whether mLOY could exert an influence on the cardiovascular risk associated with CHIP.

    Methods:

    We conducted an examination for the presence of CHIP and mLOY using targeted high-throughput sequencing and digital PCR in a cohort of 446 individuals. Among them, 149 patients from the CHAth study had experienced a first MI at the time of inclusion (MI(+) subjects), while 297 individuals from the Three-City cohort had no history of cardiovascular events (CVE) at the time of inclusion (MI(-) subjects). All subjects underwent thorough cardiovascular phenotyping, including a direct assessment of atherosclerotic burden. Our investigation aimed to determine whether mLOY could modulate inflammation, atherosclerosis burden, and atherothrombotic risk associated with CHIP.

    Results:

    CHIP and mLOY were detected with a substantial prevalence (45.1% and 37.7%, respectively), and their occurrence was similar between MI(+) and MI(-) subjects. Notably, nearly 40% of CHIP(+) male subjects also exhibited mLOY. Interestingly, neither CHIP nor mLOY independently resulted in significant increases in plasma hs-CRP levels, atherosclerotic burden, or MI incidence. Moreover, mLOY did not amplify or diminish inflammation, atherosclerosis, or MI incidence among CHIP(+) male subjects. Conversely, in MI(-) male subjects, CHIP heightened the risk of MI over a 5 y period, particularly in those lacking mLOY.

    Conclusions:

    Our study highlights the high prevalence of CHIP and mLOY in elderly individuals. Importantly, our results demonstrate that neither CHIP nor mLOY in isolation substantially contributes to inflammation, atherosclerosis, or MI incidence. Furthermore, we find that mLOY does not exert a significant influence on the modulation of inflammation, atherosclerosis burden, or atherothrombotic risk associated with CHIP. However, CHIP may accelerate the occurrence of MI, especially when unaccompanied by mLOY. These findings underscore the complexity of the interplay between CHIP, mLOY, and cardiovascular risk, suggesting that large-scale studies with thousands more patients may be necessary to elucidate subtle correlations.

    Funding:

    This study was supported by the Fondation Cœur & Recherche (the Société Française de Cardiologie), the Fédération Française de Cardiologie, ERA-CVD (« CHEMICAL » consortium, JTC 2019) and the Fondation Université de Bordeaux. The laboratory of Hematology of the University Hospital of Bordeaux benefitted of a convention with the Nouvelle Aquitaine Region (2018-1R30113-8473520) for the acquisition of the Nextseq 550Dx sequencer used in this study.

    Clinical trial number:

    NCT04581057.